Page 3 - David Devos News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from David devos. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In David Devos Today - Breaking & Trending Today

AstraZeneca EU shortfall; French quick test looking good - Delano


AstraZeneca expects to deliver less than half target
In a story the pharmaceutical company has not denied, Reuters reports that AstraZeneca has told the European Union during internal meetings that it “would deliver less than 90 million doses” of its covid-19 vaccine in the second quarter  of this year. That is less than half the Covid-19 vaccines it was contracted to supply and follows a shortfall in the first quarter. A later statement from AstraZeneca said it was attempting to increase productivity in an effort to fulfil the contract. An EU official told Reuters the bloc should still have enough doses to hit its vaccination target of 70% of the population by summer if other suppliers meet their supply promises. ....

New York , United States , France General , Los Angeles , Chuck Schumer , Jean Claude Schmit , Mahamane Ousmane , Joe Biden , Daphne Caruana Galizia , Mohamed Bazoum , Justin Trudeau , Caruana Galizia , Tiger Woods , David Devos , Carmel Chircop , University Of Lille , European Commission , New York Times , European Union , Reliability Council Of Texas , Toronto Star , Daphne Caruana , Electric Reliability Council , West African , புதியது யார்க் , ஒன்றுபட்டது மாநிலங்களில் ,

AbFero Pharmaceuticals Announces Funding From Cure Parkinson's For Lead Compound SP-420


AbFero Pharmaceuticals Announces Funding From Cure Parkinson s For Lead Compound SP-420
Second Parkinson s Grant to Clinical Stage Pharmaceutical Company Developing Iron Chelators
HARWELL, England, Feb. 17, 2021 /PRNewswire/ AbFero Ltd., a subsidiary of AbFero Pharmaceuticals, Inc., a privately-held clinical stage pharmaceutical company dedicated to treating diseases of iron overload, today announced the award of a grant from Cure Parkinson s for the development of their lead, brain-penetrant iron chelating agent, SP-420, as a disease modifying therapy for Parkinson s disease (PD).
The funding will be used to develop biomarkers to demonstrate that SP-420 is an effective targeted therapy for Parkinson s. This is the second grant AbFero has received to support development of SP-420 for the condition, following recent funding from Eureka EUROSTARS. ....

United Kingdom , Kostenloser Wertpapierhandel , Thomas Neenan , Richard Wyse , David Devos , Raymond Bergeron , University Of Lille , Research Development At Cure Parkinson , University Of Florida , Abfero Pharmaceuticals Inc , Prnewswire Abfero Ltd , Abfero Ltd , Second Parkinson , Fero Ltd , Abfero Pharmaceuticals , Cure Parkinson , Professor David Devos , Professor Raymond Bergeron , Media Contact , ஒன்றுபட்டது கிஂக்டம் , தாமஸ் நீநன் , டேவிட் டேவோஸ் , ரேமஂட் பெர்கெரான் , பல்கலைக்கழகம் ஆஃப் லில்லி , ஆராய்ச்சி வளர்ச்சி இல் குணப்படுத்த பார்கின்சன் , பல்கலைக்கழகம் ஆஃப் புளோரிடா ,